MALT Lymphoma Clinical Trial
Official title:
Phase II Trial pf Bortezomib in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type
Bortezomib for treatment of disseminated MALT lymphoma or at relapse following HP -eradication,or chemotherapy or radiation.
The objectives of this study are to evaluate the effectivity and the safety of bortezomib in
patients with disseminated MALT lymphoma or at relapse following HP-eradication, or
chemotherapy or radiation.
It is a phase II prospective single arm study with a target sample of 16 patients. 1.5mg/m2
Bortezomib is given intravenously on day 1,4,8,11 every three week, for a maximum of
8cycles.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05003141 -
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
|
Phase 1 | |
| Completed |
NCT01015248 -
Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
|
Phase 2 | |
| Completed |
NCT00373646 -
Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients
|
Phase 2 | |
| Completed |
NCT00201422 -
Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALToma
|
N/A | |
| Unknown status |
NCT00923663 -
Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type
|
Phase 2 | |
| Completed |
NCT00783367 -
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
|
Phase 2 | |
| Active, not recruiting |
NCT01808599 -
Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma
|
Phase 2 | |
| Completed |
NCT00117156 -
Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05544019 -
Study of SGR-1505 in Mature B-Cell Neoplasms
|
Phase 1 |